North American Educational Forum on Lymphoma
The Educational Forum on Lymphoma will be an in-person program, delivering patient education programming. There will be no online/hybrid option. Please see Health and Safety Policy for Lymphoma Patient Programs here. This program will provide access to local lymphoma experts. Please continue to check this page for updates. For updates on programs, please ensure you are subscribed to receive emails from the Lymphoma Research Foundation (LRF).
2024 Educational Forum on Lymphoma
Save the Dates:
Saturday, October 26 – Sunday, October 27, 2024
Location:
New York Marriott at the Brooklyn Bridge
333 Adams Street
Brooklyn, NY 11201
Program Lodging: Rooms are available through our room block at special rates. Reservations must be made by October 3. Click here for lodging/group rate information or call +1 718-246-7000.
Program Agenda
Saturday, October 26, 2024 – All times ET
Registration Desk Hours: 8:00 AM – 4:30 PM
8:30 AM – Breakfast
9:30 AM – 11:00 AM – Understanding Lymphoma and Chronic Lymphocytic Leukemia: Current Perspectives
Lymphoma and CLL Overview – Eduardo Sotomayor, MD, Tampa General Hospital
This session will focus on an overview of lymphoma, including the different types of lymphoma and chronic lymphocytic leukemia.
Emerging Treatment Options – Peter Martin, MD, Weill Cornell Medicine
The lymphoma/CLL treatment landscape is changing rapidly with new treatments. Learn about newer treatment options on the horizon. BTK inhibitors, BCL-2 inhibitors, and BTK degraders.
Clinical Trials – Jennifer Amengual, MD, Colombia University Medical Center
Every drug available today had to be tested in clinical trials before it was approved for general use. Learn more about clinical trials and the impact these studies will have for the future of lymphoma/CLL treatment.
11:00 AM – Networking Break
11:30 AM – Disease-Specific Breakout Sessions (choose one)
These sessions are an opportunity for patients and caregivers to learn more about disease biology, treatment options and clinical trials related to their specific subtype. These sessions will cover topics for newly diagnosed and relapsed/refractory patients. There will be a Question and Answer discussion at the conclusion of each presentation.
- Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma – John N. Allan, MD, Weill Cornell Medicine
- Diffuse Large B-Cell Lymphoma and Other Aggressive B-Cell Lymphomas – Hua-Jay J Cherng, MD, Columbia University Medical Center
- Follicular Lymphoma and Marginal Zone Lymphoma – Carla Casulo, MD, University of Rochester
- Hodgkin Lymphoma – Speaker TBA
- Mantle Cell Lymphoma – Anita Turner, MD, Memorial Sloan Kettering Cancer Center
- T-Cell Lymphomas (including PTCL and CTCL) – Jia Ruan, MD, Weill Cornell Medicine
- Waldenstrom Macroglobulinemia – Shayna Sarosiek, MD, Dana-Farber Cancer Institute
12:45 PM – Networking Lunch
Attendees will have the opportunity to sit at tables and network with others who have the same disease-subtype.
12:45 PM – Care Partner Lunch
1:45 PM – Update on Immunotherapies – Joanna Rhodes, MD, Rutgers Cancer Institute of New Jersey
Immunotherapy enhances the power of a patient’s immune system to attack tumors. Learn more about chimeric antigen receptor (CAR) T-cell therapy, bispecific antibodies, antibody-drug conjugates (ADC) checkpoint inhibitors and the other classes of immunotherapy that are either approved or under investigation for lymphoma patients.
2:45 PM – Networking Break
3:15 PM – Profile of Hope
3:30 PM – Lymphoma Research Foundation Scholar Panel
5:00 PM – Reception for all attendees
Sunday, October 27, 2024 – All times ET
Registration Desk Hours: 8:00 AM – 2:00 PM
8:30 AM – Breakfast
9:15 AM – How to Work with Your Healthcare Team Panel: Navigating Clinical Trials, Shared Decision Making, Seeking a Second Opinion, Supporting Mental Health
10:15 AM – Networking Break
10:30 AM – Special Lymphoma Topics Breakouts (choose one)
- Treatment Options for Transformed Lymphomas – Theodora Anagnostou, MD, Mount Sinai
Transformed lymphoma occurs when an indolent lymphoma develops into a more aggressive one. Learn more about transformed lymphomas and the treatment options available when a lymphoma transforms. - Diagnosing and Managing Lymphoma with Diagnostic and Biomarker Testing – Adam Olszewski, MD, Brown University
There have been remarkable improvements in how cancers are detected and diagnosed, including testing cancer cells for genes and proteins that may affect which treatments might be most appropriate for a patient. Learn more about how this can be applied to the diagnosis and treatment of lymphoma/CLL. - Surveillance Strategies – I’ve finished my treatment, what comes next? – Elise Chong, MD, University of Pennsylvania
After patients complete their treatment, there might be different ways that they can be monitored to maintain their health. This session will describe the types of scans, bloodwork, and other tests that can be used during follow-up care.
11:30 AM – Networking Break
11:45 AM – Lymphoma Survivorship – Emily Tonorezos, MD, National Cancer Institute
There are an increasing number of lymphoma and CLL survivors each year. Learn more about managing long-term side effects, follow-up care and the emotional impact of a lymphoma/CLL diagnosis.
12:45 PM – Break for Lunch
1:00 PM – Lunch and Learn: Nutrition – Peter Adintori, MS, RD, CSO, CDN, CNSC, Memorial Sloan Kettering Cancer Center
2:00 PM – Closing Remarks
This program is for patients and survivors, caregivers, and program supporters. If you are a pharmaceutical industry professional who is interested in attending but your company is not listed as a sponsor, please email vgonzalez@lymphoma.org to learn more about sponsorship.
Disclaimer: Lymphoma Research Foundation is a national nonprofit organization based in the United States. Its educational programs and resources are intended for a US-based audience. These programs and resources address available lymphoma treatments in the United States and information on drug approvals by the US Food and Drug Administration.